Franz Fazekas
Seconda Università degli Studi di Napoli
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Franz Fazekas.
Neurology | 1994
Reinhold Schmidt; Wolfgang Freidl; Franz Fazekas; B. Reinhart; Peter Grieshofer; M. Koch; Bernd Eber; Martin Schumacher; K. Polmin; Helmut Lechner
Article abstract We administered the Mattis Dementia Rating Scale (MDRS) to 1,001 healthy volunteers, aged 50 to 80 years, randomly selected from our community. Multivariate regression analysis revealed educational level (p = 0.000004) and age (p = 0.00001), but no other sociodemographic or risk factors for stroke, to be significantly associated with the MDRS score. The age- and education-specific lowest quintile cutoff scores ranged from 140 in subjects aged 50 to 59 years with at least college experience to 130 in subjects aged 70 to 80 years with only 4 to 9 years of schooling. These percentile distributions obtained for decades of age and different levels of education should be useful reference values for clinicians and investigators when applying the MDRS to assess cognitive functioning.
Multiple Sclerosis Journal - Experimental, Translational and Clinical | 2018
Margarete Voortman; Paul Greiner; Daniel Moser; Martin H. Stradner; Winfried Graninger; Adrian Moser; Bernd Haditsch; Christian Enzinger; Siegrid Fuchs; Franz Fazekas; Johannes Fessler; Michael Khalil
Background The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. However, pre-analytical procedures might impact test results, thereby limiting its clinical usability. Whether the immediate analysis of CD62L expression of peripheral blood mononuclear cells can aid treatment decision making is yet unclear. Objective To investigate the effect of various disease-modifying therapies in multiple sclerosis on CD62L expression of CD3+CD4+ peripheral blood mononuclear cells in freshly collected blood samples. Methods We collected peripheral blood samples from patients with clinically isolated syndrome and multiple sclerosis (baseline/follow up nu2009=u2009234/nu2009=u200998) and healthy controls (nu2009=u200951). CD62L+CD3+CD4+ expression was analysed within 1 hour by fluorescence-activated cell sorting. Results CD62L+CD3+CD4+ expression was significantly decreased in patients treated with natalizumab (nu2009=u200926) and fingolimod (nu2009=u200920) and increased with dimethyl-fumarate (nu2009=u200915) compared to patients receiving interferon/glatiramer acetate (nu2009=u200990/30) or no disease-modifying therapies (nu2009=u200953) and controls (nu2009=u200951) (p<0.001). CD62L expression showed temporal stability during unchanged disease-modifying therapy usage, but increased after natalizumab withdrawal and decreased upon fingolimod introduction. Conclusion CD62L+CD3+CD4+ expression is altered in patients treated with different disease-modifying therapies when measured in freshly collected samples. The clinical meaning of CD62L changes under disease-modifying therapies warrants further investigation.
Human Brain Mapping | 2016
Paolo Preziosa; Maria A. Rocca; Elisabetta Pagani; Christian Enzinger; Antonio Gallo; Hanneke E. Hulst; Matteo Atzori; Deborah Pareto; Gianna Riccitelli; Massimiliano Copetti; Nicola De Stefano; Franz Fazekas; Alvino Bisecco; Frederik Barkhof; Tarek A. Yousry; Maria J. Arévalo; Massimo Filippi
In a multicenter setting, we applied voxel‐based methods to different structural MR imaging modalities to define the relative contributions of focal lesions, normal‐appearing white matter (NAWM), and gray matter (GM) damage and their regional distribution to cognitive deficits as well as impairment of specific cognitive domains in multiple sclerosis (MS) patients. Approval of the institutional review boards was obtained, together with written informed consent from all participants. Standardized neuropsychological assessment and conventional, diffusion tensor and volumetric brain MRI sequences were collected from 61 relapsing‐remitting MS patients and 61 healthy controls (HC) from seven centers. Patients with ≥2 abnormal tests were considered cognitively impaired (CI). The distribution of focal lesions, GM and WM atrophy, and microstructural WM damage were assessed using voxel‐wise approaches. A random forest analysis identified the best imaging predictors of global cognitive impairment and deficits of specific cognitive domains. Twenty‐three (38%) MS patients were CI. Compared with cognitively preserved (CP), CI MS patients had GM atrophy of the left thalamus, right hippocampus and parietal regions. They also showed atrophy of several WM tracts, mainly located in posterior brain regions and widespread WM diffusivity abnormalities. WM diffusivity abnormalities in cognitive‐relevant WM tracts followed by atrophy of cognitive‐relevant GM regions explained global cognitive impairment. Variable patterns of NAWM and GM damage were associated with deficits in selected cognitive domains. Structural, multiparametric, voxel‐wise MRI approaches are feasible in a multicenter setting. The combination of different imaging modalities is needed to assess and monitor cognitive impairment in MS. Hum Brain Mapp 37:1627‐1644, 2016.
Archive | 2009
Franz Fazekas; C. Enzinger; Stefan Ropele; Reinhold Schmidt
Archive | 2018
Thomas Gattringer; C. Enzinger; Stefan Ropele; Franz Fazekas
Nature Reviews Neurology | 2015
A Rovira; Mike P. Wattjes; Mar Tintoré; Carmen Tur; Tarek A. Yousry; Maria Pia Sormani; N. De Stefano; M Filippi; Cristina Auger; Maria A. Rocca; F. Barkhof; Franz Fazekas; L. Kappos; C.H. Polman; Dh Miller; X. Montalban
Archive | 2014
Franz Fazekas; C. Enzinger; Stefan Ropele; Reinhold Schmidt
Archive | 2014
Thomas Gattringer; C. Enzinger; Michael Khalil; Petra Schwingenschuh; Alexander Pichler; Alexander Moser; Winfried Graninger; Christina Ernst; Johannes Haybaeck; Franz Fazekas
Archive | 2014
Franz Fazekas; C. Enzinger; Reinhold Schmidt; Martin Dichgans; Beate Gaertner; Gerhard Jan Jungehülsing; Michael G. Hennerici; Peter U. Heuschmann; Martin Holzhausen; Manfred Kaps; Christof Kessler; Peter Martus; Jukka Putaala; Stefan Ropele; Christian Tanislav; Turgut Tatlisumak; Bo Norrving; Arndt Rolfs
Archive | 2013
Christian Langkammer; Tian Liu; Michael Khalil; C. Enzinger; Margit Jehna; Siegrid Fuchs; Franz Fazekas; Yi Wang; Stefan Ropele